Sibannac Forms Joint Venture to Develop DEA-Compliant Psilocybin Research Facility
summarizeSummary
Sibannac, Inc. announced the signing of a Letter of Intent to form a joint venture with 1120 Management, LLC. The partnership aims to develop and operate a state-of-the-art, DEA-compliant psilocybin research, cultivation, extraction, and analytical laboratory facility in Phoenix, Arizona. This is a highly significant development for the micro-cap company, as it provides crucial infrastructure and regulatory compliance in the heavily regulated psychedelic research sector. 1120 Management will contribute dedicated facility space, substantial capital, and construction services, while Sibannac will provide scientific and operational expertise. This strategic move establishes a foundational asset for Sibannac, enabling it to pursue advanced research and potential clinical supply, aligning with recent federal initiatives to accelerate medical treatments for serious mental illness. Investors should monitor the finalization of the definitive Joint Venture Agreement and progress on DEA and FDA registrations.
At the time of this announcement, SNNC was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $0.00 to $0.03. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Access Newswire.